Страна: Сінгапур
мова: англійська
Джерело: HSA (Health Sciences Authority)
CARBIDOPA; LEVODOPA
ORGANON SINGAPORE PTE. LTD.
N04BA02
50 mg
TABLET
CARBIDOPA 50 mg; LEVODOPA 200 mg
ORAL
Prescription Only
MERCK SHARP & DOHME (AUSTRALIA) PTY LTD
ACTIVE
1992-10-12
S-IPC-MK0295B-CR-082013 LOCAL PRODUCT CIRCULAR SINEMET ® CR (car b id o p a an d levo d o p a) SINEMET ® CR is a co m b in at io n o f car b id o p a, an ar o m at ic am in o acid d ecar b o xylase in h ib it o r , an d levo d o p a, t h e m et ab o lic p r ecu r so r o f d o p am in e, in a p o lym er -b ased co n t r o lled -r elease t ab let f o r m u lat io n , f o r u se in t h e t r eat m en t o f Par kin so n 's d isease an d syn d r o m e. SINEMET CR is p ar t icu lar ly u sef u l t o r ed u ce "o f f " t im e in p at ien t s t r eat ed p r evio u sly w it h a co n ven t io n al levo d o p a/ d ecar b o xy lase in h ib it o r co m b in at io n w h o h av e h ad p r ed ict ab le p eak -d o se d yskin esias an d u n p r ed ict ab le m o t o r f lu ct u at io n s. Pat ien t s w it h Par kin so n 's d isease t r eat ed w it h p r ep ar at io n s co n t ain in g levo d o p a m ay d evelo p m o t o r f lu ct u at io n s ch ar act er ized b y en d -o f -d o se f ailu r e, p eak d o se d yskin esia, an d akin esia. Th e ad v an ced f o r m o f m o t o r f lu ct u at io n s ("o n -o f f " p h en o m en o n ) is ch ar act er ized b y u n p r ed ict ab le sw in g s f r o m m o b ilit Прочитайте повний документ
S-IPC-OG0295B-CR-062023 LOCAL PRODUCT CIRCULAR SINEMET® CR (carbidopa and levodopa) SINEMET® CR is a combination of carbidopa, an aromatic amino acid decarboxylase inhibitor, and levodopa, the metabolic precursor of dopamine, in a polymer-based controlled-release tablet formulation, for use in the treatment of Parkinson's disease and syndrome. SINEMET CR is particularly useful to reduce "off" time in patients treated previously with a conventional levodopa/decarboxylase inhibitor combination who have had predictable peak-dose dyskinesias and unpredictable motor fluctuations. Patients with Parkinson's disease treated with preparations containing levodopa may develop motor fluctuations characterized by end-of-dose failure, peak dose dyskinesia, and akinesia. The advanced form of motor fluctuations ("on-off" phenomenon) is characterized by unpredictable swings from mobility to immobility. Although the causes of the motor fluctuations are not completely understood, it has been demonstrated that they can be attenuated by treatment regimens that produce steady plasma levels of levodopa. Levodopa relieves the symptoms of Parkinson's disease by being decarboxylated to dopamine in the brain. Carbidopa, which does not cross the blood-brain barrier, inhibits only the extracerebral decarboxylation of levodopa, making more levodopa available for transport to the brain and subsequent conversion to dopamine. This normally obviates the necessity for large doses of levodopa at frequent intervals. The lower dosage reduces or may help eliminate gastrointestinal and cardiovascular side effects, especially those which are attributable to dopamine being formed in extracerebral tissues. SINEMET CR is designed to release the active ingredients over a 4- to 6-hour period. With this formulation there is less variation in plasma levodopa levels and the peak plasma level is 60% lower than with conventional SINEMET. In clinical trials, patients with motor fluctuations experienced reduced "off" time with SINEMET CR when compared with SINEME Прочитайте повний документ